bHyaluronic acid (HA) is used in a wide range of medical applications, where its performance and therapeutic efficacy are highly dependent on its molecular weight. In the microbial production of HA, it has been suggested that a high level of intracellular ATP enhances the productivity and molecular weight of HA. Here, we report on heterologous HA production in an -poly-Llysine producer, Streptomyces albulus, which has the potential to generate ATP at high level. The hasA gene from Streptococcus zooepidemicus, which encodes HA synthase, was refactored and expressed under the control of a late-log growth phase-operating promoter. The expression of the refactored hasA gene, along with genes coding for UDP-glucose dehydrogenase, UDP-N-acetylglucosamine pyrophosphorylase, and UDP-glucose pyrophosphorylase, which are involved in HA precursor sugar biosynthesis, resulted in efficient production of HA in the 2.0 MDa range, which is greater than typical bacterial HA, demonstrating that a sufficient amount of ATP was provided to support the biosynthesis of the precursor sugars, which in turn promoted HA production. In addition, unlike in the case of streptococcal HA, S. albulus-derived HA was not cell associated. Based on these findings, our heterologous production system appears to have several advantages for practical HA production. We propose that the present system could be applicable to the heterologous production of a wide variety of molecules other than HA in the case their biosynthesis pathways require ATP in vivo.H yaluronic acid (HA) is a linear, uniformly repetitive glycosaminoglycan composed of up to 20,000 disaccharide units of D-glucuronic acid (GluUA) and N-acetylglucosamine (GlcNAc) (1) and ubiquitously exists as hydrogel in vertebrate tissues. HA is particularly abundant in cartilage, synovial fluid, dermis, and the vitreous humor of the eye. In these tissues, the polysaccharide has significant structural, physiological, and biological functions due to its viscoelastic property and ability to retain a large volume of water (2). These distinctive properties have been exploited in a wide range of medical applications, including in the areas of ophthalmology, orthopedics, and wound healing (3), where the performance and therapeutic efficacy of HA are highly dependent on its molecular weight. Product quality is also considered a key factor for these biomedical applications in order to avoid serious allergic and inflammatory reactions caused by contaminants, especially upon injection (4, 5). Thus, to meet the growing demand for HA in the field of biomedicine (6), it is critical to produce high-molecular-weight HA from a safe source that does not carry those concerns.Traditionally, HA had been obtained commercially from rooster corms, but in recent years it has mainly been produced through the fermentation process of an attenuated pathogenic strain of group C streptococci that naturally synthesize the identical macromolecule as a part of the extracellular capsule in order to conceal it from the immune system of...